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ABSTRACT 54 
Background: Hypertension is poorly controlled. Team-based care and changes in the 55 
process of care have been proposed to address these quality problems. However, 56 
assessing care processes is difficult because they are often confounded even in 57 
randomized behavioral studies by unmeasured confounders based on discretion of 58 
healthcare providers.  59 
Objective: To evaluate the effects of process measures including number of counseling 60 
sessions about lifestyle modification and number of antihypertensive medications on 61 
blood pressure change and payer-perspective treatment costs.  62 
Methods: Data were obtained from two prospective, cluster randomized controlled 63 
clinical trials (Trial A and B) implementing physician-pharmacist collaborative 64 
interventions compared with usual care over six months in community-based medical 65 
offices in the Midwest. Multivariate linear regression models with both instrumental 66 
variable methods and as-treated methods were utilized. Instruments were indicators for 67 
trial and study arms. Models of blood pressure change and costs included both process 68 
measures, demographic variables, and clinical variables. 69 
Results: The analysis included 496 subjects. As-treated methods showed no significant 70 
associations between process and outcomes. The instruments used in the study were 71 
insufficient to simultaneously identify distinct process effects. However, the post-hoc 72 
instrumental variable models including one process measure at a time while controlling 73 
for the other process demonstrated significant associations between the processes and 74 
outcomes with estimates considerably larger than as-treated estimates.  75 
Conclusions: Instrumental variable methods with combined randomized behavioral 76 
studies may be useful to evaluate the effects of different care processes. However, 77 
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substantial distinct process variation across studies is needed to fully capitalize on this 78 
approach. Instrumental variable methods focusing on individual processes provided 79 
larger and stronger outcome relationships than those found using as-treated methods 80 
which are subject to confounding.  81 
 82 
 83 
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INTRODUCTION 102 
The Institute of Medicine has suggested that health care is often not delivered 103 
optimally with either overutilization or underutilization of certain services which can lead 104 
to medical errors.
1
 On average, patients with hypertension received the recommended 105 
quality of care only 65% of the time based on a list of 27 quality measures regarding 106 
physical examination, history, laboratory tests, counseling or education, appropriate 107 
medication, and encounter or intervention.
2
 Less than optimal quality of care such as 108 
failure to intensify therapy when clinically indicated may explain why only 39% of visits 109 
for hypertension were at recommended blood pressure (BP) goals according to JNC 7 110 
guidelines (Seventh report of the Joint National Committee on Prevention, Detection, 111 
Evaluation, and Treatment of High Blood Pressure).
3
 112 
Several proposed changes to ameliorate quality-of-care problems include 113 
reorganizing practices to meet the needs of patients through multidisciplinary 114 
teamwork
1,4,5
 and assessing both outcomes and processes of care.
6,7
 Process of care 115 
measures for patients with hypertension including screening, diagnosis, treatment, and 116 
follow-up have been proposed.
2 Treatment and follow-up processes such as counseling 117 
and utilization of antihypertensive medications may be more strongly related to outcomes 118 
than other processes such as diagnosis that primarily determine the cause of 119 
hypertension.
8
 The few studies attempting to demonstrate a link between processes and 120 
outcomes exhibited certain limitations such as insufficient variation in process measures
9
, 121 
lack of control for the effects of other processes
10
, and potential unmeasured confounders 122 
biasing estimated relationships between process and outcome.
8,9,11
 123 
In randomized studies of process improvement interventions, the average effect of 124 
the total process improvement package is validly estimated through intention-to-treat 125 
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analyses. However, it is often desirable to know the contribution of each individual 126 
process in the package to the outcomes achieved. As long as the providers who are 127 
delivering the intervention have discretion in the types or level of processes to deliver, 128 
there is an opportunity to evaluate how this variability relates to outcomes.   129 
The confounding problem intrinsic to as-treated analyses of such “randomized 130 
process studies with discretion” can be alleviated using instrumental variable (IV) 131 
estimators.
12,13
 IV estimators use randomization as the “instrument” to exploit only the 132 
process change related to randomization when assessing the effects of process on 133 
outcomes. However, when employing this IV approach using a single randomized study, 134 
it is only possible to assess the effects of a single process measure. This study tried to 135 
ascertain the distinct effects of patient counseling and drug utilization processes on 136 
outcomes for patients with hypertension by employing two techniques: mega-trial 137 
analysis
14
 and IV methods. Individual patient data from two prospective, cluster 138 
randomized controlled clinical trials implementing physician-pharmacist collaborative 139 
interventions for treating hypertension were combined and the data were analyzed as if 140 
they were from a single trial (mega-trial analysis). These interventions were designed 141 
with distinct characteristics in treating patients, which were theorized to lead to 142 
differences in the amount of patient counseling and drugs prescribed to patients and thus 143 
became an instrument for IV methods. The study objective was to evaluate the effects of 144 
the number of counseling sessions about lifestyle modification and the number of 145 
antihypertensive medications over six months on BP change and treatment costs by 146 
comparing the estimates from as-treated and IV methods. 147 
 148 
 149 
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METHODS 150 
Data and study period 151 
The data were obtained from two prospective, cluster randomized controlled 152 
clinical trials, namely trial A in 2009
11
 and trial B in 2008
15
 by Carter and colleagues. 153 
Further description of the studies has been published previously.
11,15
 Both trials examined 154 
the ability of physician-pharmacist collaborative interventions to improve BP control 155 
compared with usual care. The two trials were similar with respect to patient selection 156 
and baseline characteristics (Table A1 in Appendix A), methods to implement the 157 
interventions, and outcome measurement. The homogeneity test evaluating the 158 
consistency of the collaborative intervention effects across trials for meta-analysis 159 
showed that the variability in the intervention effects between the two studies was likely 160 
to be due to chance alone (Appendix B).  161 
Trial A implemented a 6-month collaborative intervention whereas trial B 162 
implemented a 9-month intervention and measured BP at six months. For consistency this 163 
study evaluated 6 months of data from both trials. The number of subjects was slightly 164 
different from the totals across the original trials because the subjects included in this 165 
study were required to complete 6 months in their respective study to provide healthcare 166 
utilization data to estimate treatment costs. 167 
The use of 6-month data of trial B implementing the 9-month intervention is 168 
valid because the process of care mostly occurred in the first few months and BP 169 
outcomes at six months and those at nine months were similar. In trial B, the vast 170 
majority of pharmacist recommendations to change medications occurred in the first 171 
two months of the intervention (77%) and only 12% occurred between the 6-9 month 172 
visits.
16
 From those pharmacist recommendations, 97% of them were accepted by 173 
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physicians. So, the number of recommendations nearly equal the number of drug 174 
changes. Additionally, approximately 58% of drug therapy changes occurred in the 175 
first month in trial B while 55% of that occurred in the first month in trial A.
17
 176 
Moreover, the average systolic and diastolic blood pressure (SBP and DBP, 177 
respectively) in mm Hg in the intervention group of trial B at six months were 178 
126.6(standard deviation (SD) =11.9)/76.1(10.3) similar to that at nine months which 179 
were 124.2(9.7)/74.7(9.6).
15
 Therefore, the 6-month individual patient data from the 180 
two trials were combined. 181 
Both trials prospectively and systematically collected the data about the care 182 
processes of the interventions, BP outcomes, and healthcare utilization during the study 183 
period. The interventions involved clinical pharmacists who were faculty members in 184 
medical offices. They collaborated with primary care physicians through face-to-face, 185 
phone, and written communication. Each clinical pharmacist had a PharmD-degree, and 186 
nearly all were residency trained. Their primary focus was addressing suboptimal 187 
medication regimens, recommending therapies consistent with JNC 7 guidelines
18
, and 188 
educating physicians with background information if necessary. The number of 189 
counseling sessions dealing with lifestyle modification for (1) weight reduction, (2) 190 
dietary approaches to stop hypertension (DASH), (3) sodium restriction, (4) increasing 191 
physical activity, (5) decreasing alcohol consumption and (6) others such as smoking 192 
cessation that were provided by either physicians or pharmacists during the interventions 193 
was counted for each patient. Moreover, types and doses of antihypertensive medications 194 
prescribed and the changes in the regimens during the study period were collected for 195 
each patient. Baseline characteristics and BP outcomes were collected by the research 196 
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nurses. Treatment costs were obtained from a companion cost-evaluation study utilizing 197 
data from the same two trials.
19 198 
 199 
Subjects and settings 200 
Subjects from the trials were patients aged 21 years or older with a diagnosis of 201 
essential hypertension. The recruited subjects represented prevalent cases where BP 202 
remained uncontrolled at baseline. The trials assigned 11 community-based medical 203 
offices in the Midwest to be in either the intervention group or the usual care group. Five 204 
community-based medical offices were assigned to be the intervention group and six in 205 
the control group.  206 
 207 
Outcomes 208 
Dependent variables included SBP change, DBP change, and treatment costs at 209 
six months. BP change was the difference between BP at six months and at baseline (mm 210 
Hg; a minus sign refers to reduction). Measurement of BP followed the standard 211 
guidelines.
20
 BP was measured by trained nurses three times on the same day using a 212 
previously used protocol
21
; then the second and the third values were averaged to be the 213 
study BP. Both studies used 24-hour BP monitoring to ensure the reliability of the nurse-214 
measured BP data.  215 
Treatment costs were estimated from the payer’s perspective from each patient’s 216 
utilization related to primary care physician time, specialist time, pharmacist time, 217 
overhead, laboratory tests, and antihypertensive medications, multiplied by the respective 218 
prices per unit.
19
 The amount of primary care physician, specialist, and pharmacist time 219 
allocated to each patient was estimated from number of direct patient care and 220 
This is a post-refereeing version submitted to RSAP. The published version is available at doi:10.1016/j.sapharm.2014.07.007 
10 
 
collaboration activities a patient received multiplied by average time (minutes) per 221 
activity. Estimates of minutes per activity were based on averages from survey responses. 222 
The National Ambulatory Medical Care Survey in 2003 provided average physician visit 223 
time. A second survey of pharmacists involved in the two Carter studies (the response 224 
rate was 87.5%) provided estimates of the average times to perform the lifestyle 225 
modification activities. The estimates were consistent across trials. From both trials, 226 
average times spent for each activity included 10.4 minutes for a weight reduction 227 
session, 7.7 minutes for a session describing the DASH plan, 5.8 minutes for sodium 228 
reduction discussions, 6.5 minutes for discussion to increase physical activity, 4.2 229 
minutes to discuss decrease in alcohol consumption, and 7.3 minutes to encourage 230 
smoking cessation. Provider wage rates were obtained from published reports for primary 231 
care physicians ($79.64), specialists ($77.64), and pharmacists ($50.14) in 2008 value.
22
 232 
Each laboratory test was assigned its costs from the Medicare laboratory fee schedule.
23
 233 
Medication costs considered changes in the regimens including starting a new medication 234 
and changing a dose during the study period. The market cost per day of the medication 235 
was estimated from a generic version, if available, with a 30-day supply. Total treatment 236 
costs were eventually adjusted to the US dollar values in 2013 using overall medical care 237 
price indexes obtained from the Bureaus of Labor Statistics.
24
    238 
 239 
Process-of-care measures  240 
 The number of counseling sessions received by each patient was measured by 241 
summing the number of all lifestyle modification sessions provided by both physicians 242 
and pharmacists to each patient over the study period of six months. Lifestyle 243 
modification counseling included weight reduction, DASH, sodium restriction, increasing 244 
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physical activity, decreasing alcohol consumption, and others such as smoking cessation. 245 
The number and types of counseling sessions provided to each patient in the studies were 246 
left to provider discretion. It was assumed that the counseling was provided at equally 247 
acceptable quality to all subjects because all of the intervention pharmacists possessed a 248 
PharmD degree and nearly all of them had residency training and received similar 249 
training for the intervention. Moreover, only faculty physicians provided care to subjects 250 
in the trials. Therefore, given equal quality of counseling, number of counseling sessions 251 
reflects the impact of the quantity of counseling. 252 
The measure of use of antihypertensive agents for each patient was the total 253 
number of specified-dose antihypertensive medications prescribed during the study 254 
period. This measure counted every specific dose of an antihypertensive agent prescribed. 255 
If a specific dose was discontinued and a new dose of the same agent was started, the 256 
count was two. However, a reorder or restart of the same dose of the same agent was not 257 
counted. Also, if it is assumed that patients purchased the medications and took them as 258 
prescribed, this measure represents the impact of all antihypertensive agents a patient 259 
experienced to lower his/her BP during the study period.  260 
 261 
Control variables 262 
Control variables included age, gender, race/ethnicity, marital status, smoking 263 
status, alcohol intake, number of antihypertensive medications at baseline, number of co-264 
existing conditions, SBP at baseline, and DBP at baseline. The co-existing conditions 265 
included diabetes mellitus, peripheral artery disease, left ventricular hypertrophy, 266 
coronary bypass surgery, stroke, chronic kidney disease, heart failure, angina, and 267 
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myocardial infarction. The control variables were the predictors of BP control and 268 
healthcare utilization suggested by the previous literature.
25-27 269 
Our model did not specify a measure of adherence to antihypertensive 270 
medications because the data were missing for 17% of subjects (Appendix C). Subject 271 
adherence to medications was measured by self-reported responses to the Morisky scale; 272 
adherence was defined as answering no to 3 or more of 5 questions.
11
 There was no 273 
statistically significant difference in number of subjects who were adherent between the 274 
intervention and the usual care groups for each trial (89% vs. 91% in trial A (p-value = 275 
0.51) and 96% vs. 93% in trial B (p-value = 0.43), respectively). Also, no statistical 276 
difference in adherence was found across the trials (p-value = 0.13). 277 
   278 
Analysis 279 
Discretion in the number of counseling sessions provided to each patient and the 280 
number of medications prescribed to each patient was allowed in both trials A and B.  281 
The trials differed in the minimum number of required pharmacist contacts in the 282 
intervention groups. Trial A specified two pharmacist visits and one telephone call over 283 
six months, while trial B required four pharmacist visits over six months. Beyond the 284 
required protocols, additional phone calls or visits were allowed at the discretion of 285 
pharmacists if BP was not controlled. Neither trial required a minimum number of 286 
physician visits. Physician visits were scheduled at discretion of physicians in both the 287 
intervention group and the usual care group of studies.  288 
The discretion available to providers in the in the trials to initiate counseling 289 
sessions and prescribe medications may cause bias in estimating the effects of these 290 
processes on outcomes when using as-treated methods. For example, additional care 291 
This is a post-refereeing version submitted to RSAP. The published version is available at doi:10.1016/j.sapharm.2014.07.007 
13 
 
processes may have been provided to subjects with more severe clinical circumstances 292 
that were unmeasured in our data. If higher measured severity has direct negative effects 293 
on BP reduction and positive effects on healthcare costs, then directly estimated 294 
relationships between processes and BP reductions will be biased low and the 295 
relationships between the processes and healthcare costs will be biased high. 296 
To address bias caused by unmeasured confounders driven by discretion, IV 297 
methods were utilized. IV methods provide an alternative approach to addressing 298 
problems with unmeasured confounders by using “instruments” to isolate the variation in 299 
the processes of care that is not associated with unmeasured confounders.
13,28
 Instruments 300 
are measured variables that must be correlated with process of care (instrument relevance 301 
property), but are uncorrelated with unmeasured factors affecting outcomes and have no 302 
direct effect on outcomes (instrument exogeneity property). For typical studies, 303 
randomization at a patient level is a natural instrument because patients are randomized 304 
into intervention and control arms which will affect the processes they receive and 305 
randomization is not correlated with unmeasured factors or directly related with 306 
outcomes.
29
 307 
To identify distinct process effects, the number of instruments in an IV study must 308 
be greater than or equal to the number of processes being analyzed and the instruments 309 
must have independent effects on each process.
28,30
 The second condition is needed 310 
because IV estimation only uses the variation in the process measures that is associated 311 
with the instruments. If the instruments affect each process measure in the same manner, 312 
there will be insufficient variation in each process measure identified by the instruments 313 
to estimate the independent effect of each process on the outcome.  314 
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An example of an IV estimator is a two-stage least square estimator.
31
 In the first 315 
stage, separate choice equations are estimated for each process of care as a function of 316 
specified instruments and control variables. Then, in the second stage, the outcome is 317 
regressed on control variables and each predicted process of care level produced by the 318 
first stage models.
28,32
 The estimated effects of processes on outcomes in the second-319 
stage regression are appropriately generalized to the subset of patients whose processes of 320 
care are affected by the instrument(s).
33
 321 
To operationalize IV methods in this study had two instruments available: the 322 
cluster randomization at the clinic level within each study; and the distinct design 323 
differences between trials with respect to number of provider visits. Both instruments 324 
were theorized to influence contacts that subjects had with providers which in turn 325 
affected both the amount of counseling and antihypertensive medications each subject 326 
received. These instruments divided the patients from the study into three groups: the 327 
intervention subjects from trial A; the intervention subjects from trial B; and the usual 328 
care subjects from both trials. The exogeneity requirement for both instruments should be 329 
satisfied because the two trials recruited very similar subjects with hypertension based on 330 
the similar inclusion and exclusion criteria, it was expected that the cluster randomization 331 
and the study designs would not be correlated with unmeasured factors affecting study 332 
outcomes. However, this may not always be the case because cluster randomization at a 333 
clinic level may not fully balance patient characteristics between groups. 334 
Descriptive statistics of the covariates, process measures, and outcomes between 335 
three groups divided by the instruments of cluster randomization and the study designs 336 
were calculated to help assess the extent that the property of exogeneity held here.  337 
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The IV models were estimated using two-stage least squares (2SLS). The fully-338 
specified 2SLS model for each outcome model included a first-stage counseling equation 339 
and a first-stage antihypertensive medication utilization equation. Each first-stage 340 
regression equation was explained by the control variables and two indicator variables of 341 
the instruments (the first indicator variable = 1 if the subject was in the intervention 342 
group in trial A, 0 otherwise; and the second indicator variable = 1 if the subject was in 343 
the intervention group in trial B, 0 otherwise; and the usual care groups in both trials 344 
were the reference group). In the second-stage of 2SLS, the predicted number of 345 
counseling events, the predicted number of specified-dose antihypertensive medications, 346 
and the same set of control variables were used to estimate the process effects on the 347 
outcome.  348 
The F-tests for the first-stage regression models were used to assess whether the 349 
instruments had significant effects on the process measures.  However, in a two process 350 
model such as this, estimation also requires that the predicted process measures from 351 
each first-stage regression equation contained sufficient independent information to 352 
estimate the distinct effects of each process. Lack of independent variation is called 353 
“under-identification” and is akin to multicollinearity in standard multiple regression 354 
models. The Kleibergen-Paap test was used to assess whether the outcome equation of 355 
the second-stage regression was sufficiently identified. A statistically significant 356 
Kleibergen-Paap test signifies sufficient identification.
34
   357 
If under-identification was found in the fully-specified models, post-hoc IV 358 
models including one process measure at a time while directly controlling for the actual 359 
value of other process measure will be utilized. This post-hoc IV method is akin to ridge 360 
regression approaches that mediate the effects of multicollinearity in multiple regression 361 
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models by adding random variation to the independent variables to break up relationships 362 
among them.
35,36
 This approach produces biased coefficient estimates but often 363 
substantially reduces estimated standard errors thereby providing more precise upper and 364 
lower bounds for the true parameter values.   365 
As a comparison, ordinary-least-squares (OLS) linear regression models were 366 
utilized to estimate the effects of the processes on outcomes using an as-treated approach. 367 
The outcome model was explained by number of counseling sessions about lifestyle 368 
modification, number of specified-dose antihypertensive medications, and the control 369 
variables.  370 
For consistency, linear specification was used for both as-treated and IV models. 371 
In addition, robust standard errors were estimated throughout because the distribution of 372 
the error terms across observations was unknown. The unit of the analysis was the 373 
individual subject.   374 
SAS version 9.3 was used in managing data and performing descriptive statistics, 375 
comparisons, and diagnostic tests. Stata version 11.2 was used for the regression analysis 376 
(syntax: regress and ivreg2 with the robust option). A significance level of 5% was 377 
utilized for all analyses.  378 
 379 
RESULTS 380 
Descriptive statistics 381 
Across both studies, 496 subjects were included. The sample patients had an 382 
average age of 60.15 years (SD = 13.32) and 60% were female. The majority of the 383 
subjects (88%) were Caucasians. On average, subjects took 1.50 (SD = 1.03) 384 
antihypertensive medications at baseline. Approximately 63% of the sample had no co-385 
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existing condition at baseline and the majority of the remaining had one condition (30%). 386 
Smokers represented 19% of the sample and 14% drank alcohol daily. The mean SBP 387 
and DBP at baseline were 152.16 (SD = 12.30) and 84.76 (SD = 11.90) mm Hg, 388 
respectively. To explain subjects excluded from the pool of subjects from trials A and B 389 
due to the requirement of complete 6-month data, there were 85 excluded subjects and 390 
51% were female. The average age was 53 years and 60% of them were white/Caucasian. 391 
Although the excluded subjects were relatively younger than the included subjects, the 392 
average BP outcomes of the included subjects (N = 496) were in the range of the BP 393 
outcomes from the subjects in their original trials.
11,15,19
 394 
Table 1 contains average outcome, process of care, and baseline subject 395 
characteristic measures among the three subject groups defined by the instruments. On 396 
average, patients in trial A had 2.65 counseling sessions and 3.93 specified-dose 397 
antihypertensive medications whereas patients in trial B had 3.67 counseling sessions and 398 
4.49 specified-dose antihypertensive medications. These counseling sessions were 399 
provided mostly by pharmacists (73% of the counseling sessions in the intervention 400 
groups were performed by pharmacists). Further details about time of counseling sessions 401 
by types of providers can be found in a separate study.
19
 Average processes measures 402 
were highest in the intervention group from trial B in which the protocol specified the 403 
highest minimum number of pharmacist visits as compared to the intervention group 404 
from trial A and the combined usual care group. The intervention group from trial B had 405 
the greatest unadjusted SBP reduction (25.82 mm Hg compared with 21.24 mm Hg from 406 
the intervention in trial A and 10.44 mm Hg from the usual care groups in both trials). 407 
The difference in SBP of 5 mm Hg is considered clinically significant because it 408 
approximately reduces incidence of coronary heart diseases events and stroke by 10 to 409 
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20%.
37 However, the intervention group from trial A had the highest DBP reduction (9.51 410 
mm Hg) and the highest treatment costs ($792.44). These findings suggest that the 411 
process changes resulting from the randomization and the distinct characteristics between 412 
the two trials influenced BP changes and treatment costs.  413 
Moreover, from Table 1, eight baseline measured covariates were quite similar 414 
across the three groups while six characteristics had slight to moderate differences across 415 
groups. The variables with differences were percentages of African-American subjects, 416 
subjects of other races, subjects who were married or lived as married, current smokers, 417 
subjects who never smoked, and subjects consuming alcohol. These variables were 418 
directly controlled for in our analysis, but they could be symptomatic of other 419 
unmeasured differences in potential confounders across practices.    420 
 421 
As-treated methods 422 
Table 2 shows as-treated estimates of number of counseling sessions and number 423 
of specified-dose antihypertensive medications on study outcomes. Neither process 424 
measure had a statistically significant impact on SBP or DBP. In contrast, both process 425 
measures had statistically significant positive relationships with total costs. An additional 426 
counseling session about lifestyle modification would increase in total costs by $33.02 427 
(SE = $4.69, 95% CI = ($23.80, $42.24), p-value < 0.001) and an additional specified-428 
dose antihypertensive medication was associated with an increase in total costs by $90.57 429 
(SE = $8.74, 95% CI = ($73.41, $107.74), p-value < 0.001). Full parameter estimates are 430 
available in Appendix D. 431 
 432 
 433 
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IV methods 434 
The first-stage F test statistics showed that the combined study instruments had 435 
significant effects on number of counseling sessions (F-statistic of 37.02, p-value < 436 
0.001) and number of specified-dose antihypertensive medications (F-statistic of 47.02, 437 
p-value < 0.001).  438 
Next, under-identification tests were conducted to assess whether the predicted 439 
process values were sufficiently independent to enable estimation of distinct process 440 
effects on each outcome. Unfortunately, the Kleibergen-Paap rk LM statistics failed to 441 
reject the null hypothesis (p-value = 0.50), suggesting that the fully-specified IV models 442 
which included  both predicted process measures from the first-stage models were not 443 
sufficiently identified. Further investigation was conducted and it was found that the 444 
predicted number of counseling sessions and the predicted number of specified-dose 445 
antihypertensive medications was significantly correlated (correlation coefficient = 0.24; 446 
p-value < 0.001). Moreover, variance inflation factors were estimated and compared with 447 
the cut-off point of 10 which is generally used to ascertain whether multicolinearity 448 
problems exist. The variance inflation factor of the predicted number of counseling 449 
sessions were extremely high (236.62), meaning that the standard error of the predicted 450 
number of counseling sessions was 15.4 (square root of 236.62) times larger than it 451 
would have been if it was uncorrelated with the other independent variables. The variance 452 
inflation factor of the predicted number of specified-dose antihypertensive medications 453 
was 101.52.  454 
Each fully-specified IV model (Table 2) showed no associations between the 455 
process measures and SBP change, DBP change and treatment costs. Full parameter 456 
estimates are available in Appendix D. However, especially notable are the large standard 457 
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errors associated with each process estimate which signifies a multicollinearity problem. 458 
In each fully-specified IV model insufficient variation was available from each predicted 459 
process to accurately assess the effect of each process on outcomes.  460 
 461 
Post-hoc IV analysis 462 
The results from post-hoc IV models (Table 2) demonstrated that each process 463 
measure was significantly associated with every outcome (p-value < 0.001) with 464 
coefficient standard errors substantially smaller than in the fully-specified IV models. 465 
These results show that an additional counseling session by either a physician or a 466 
pharmacist was associated with SBP and DBP reduction by 5.30 mm Hg (SE = 1.13 mm 467 
Hg) and 1.65 mm Hg (SE = 0.52 mmHg), respectively. An additional counseling session 468 
was also associated with additional total cost of $89.08 (SE = $14.74) over six months.  469 
Furthermore, an additional specified-dose antihypertensive medication reduced SBP and 470 
DBP by 7.19 mm Hg (SE = 1.57 mm Hg) and 2.68 mm Hg (SE = 0.81 mm Hg), 471 
respectively. An added medication was associated with additional total cost of $191.81 472 
(SE = $25.08).  473 
 474 
DISCUSSION 475 
This study aimed to estimate the marginal effects of the number of counseling 476 
sessions about lifestyle modification and the number of specified-dose antihypertensive 477 
medications on SBP change, DBP change and treatment costs. These effects were 478 
estimated and compared by using both as-treated methods and IV methods. The as-479 
treated models did not yield statistically significant relationships between the process 480 
measures and both SBP and DBP change but showed positive relationships between both 481 
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processes and total costs. However, since the process choices were discretionary in each 482 
study, it is possible that providers applied more of each process to patients with greater 483 
unmeasured severity and those patients tended to consume larger healthcare resources. It 484 
was expected that this would result in as-treated process effect estimates on SBP and 485 
DBP change that were biased low and effects on total cost that were biased high.  486 
When utilizing fully-specified IV models to address unmeasured confounders, the 487 
models were unidentified. Even though the instruments significantly explained the 488 
variation in each process measure as shown by the F-statistics from the first-stage 489 
regressions, the variation in the process measures isolated by the instruments was not 490 
sufficient to estimate distinct process effects on each outcome. It appears that, even 491 
though the interventions differed between trials, these differences were unable to generate 492 
sufficient differences in how the two processes were offered to patients across the studies. 493 
In the post-hoc IV models, however, both process measures were associated with 494 
reductions in SBP, and DBP and increased total costs. These estimates are potentially 495 
biased from the inability to fully control for the portion of the variation in the other 496 
process measure that was associated with the instruments. Because both process measures 497 
likely reduce BP, it is likely that these post-hoc IV estimates reflect upper bounds of the 498 
true effects. However, given the substantially smaller standard errors of the post-hoc IV 499 
estimates relative to the fully-specified IV models, the confidence intervals around the 500 
post-hoc IV estimates provide a defensible range for the true parameter values.  501 
The signs of the estimates from the post-hoc IV models and the as-treated models 502 
were the same. However the magnitudes of the estimates were quite different. The post-503 
hoc IV models revealed considerably larger reductions in SBP and DBP and higher total 504 
costs associated with unit changes in each process. These results suggest that relying on 505 
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as-treated estimates to assess the effects of provider counseling sessions and use of 506 
antihypertensive medications will understate the benefits of these processes and overstate 507 
their effects on healthcare costs.  508 
In comparing the results of the present study to the previous literature, Inkster et 509 
al. (2005) could not find any association between pharmacotherapy processes and BP 510 
control.
9
 Their observational study using a sample from eight general practices in the 511 
United Kingdom found that three or more BP lowering drugs (vs. one drug) was not 512 
associated with BP control (adjusted odds ratio = 1.31, 95% CI = 0.96 to 1.79). This was 513 
similar to the present study whereby the association between BP reduction and number of 514 
specified-dose antihypertensive agents from the as-treated models was not found. This 515 
finding is likely due to the fact that subjects with the most difficult to control BP required 516 
more medications and yet, had less of an effect on BP. 517 
In addition, Inkster and colleagues found that a higher number of consultations 518 
led to an increased likelihood of having inadequate BP control. In contrast, this present 519 
study did not find any significant relationship between number of counseling sessions and 520 
BP reduction from the as-treated models. The results from the previous study might have 521 
been due to the fact that unmeasured confounders such as severity of BP generally caused 522 
physicians to provide more counseling sessions to patients with uncontrolled BP. The 523 
present study shows that IV methods may be useful to remove some bias caused by 524 
unmeasured confounders driven by health provider discretion.  525 
A study by Brooks et al. observed a disparity between IV and as-treated estimates 526 
of the process effects on costs.
13
 Using the data from a randomized controlled trial, their 527 
study evaluated the impact of the evidence-based acute pain management practices on 528 
inpatient cost changes. The estimate from the IV methods showed that such practices 529 
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resulted in a drop of inpatient costs by $1,602, which was largely greater than the 530 
estimate of the inpatient cost reduction by $58 by using as-treated methods.   531 
The following limitations of this study are acknowledged. Considerable 532 
differences in baseline characteristics remained between the groups of patients divided by 533 
the instruments according to Table 1 partly due to the cluster randomization of the clinics 534 
to avoid contamination of the intervention at the physician level. It may be difficult to 535 
fully justify that the instruments were uncorrelated with unmeasured factors affecting 536 
outcomes (instrument exogeneity property). If the correlation between the instruments 537 
and the unmeasured factors has the opposite direction with the correlation between the 538 
instruments and the control variables, the IV estimates will be biased low. Likewise, if 539 
those correlations have the same direction, the IV estimates will be biased high. 540 
As stated earlier, the present study was unable to estimate the individual effect of 541 
a process of care controlling for other processes due to a limited number of instruments 542 
and issues about independent variation of each process measure. Further research may be 543 
needed to address the under-identification issue by having interventions which have the 544 
same sets of care processes but different focuses on the care. This approach may extract 545 
process variation sufficient to estimate the effect on outcomes. For instance, an 546 
intervention from one study could primarily focus on changes in pharmacotherapy and an 547 
intervention from the second study might heavily emphasize on counseling sessions 548 
about lifestyle modifications. Thus, the instrument of distinct characteristics between the 549 
two studies should increase variation in each process measure. Moreover, future research 550 
should combine more than two studies to attain distinct characteristics between the 551 
studies and use that as the instruments. The application of the IV approach and 552 
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combining multiple randomized studies may be used as a meta-analysis of behavioral 553 
interventions to further show the effects of each process embedded in the interventions.   554 
Furthermore, the results may not apply to different settings such as non-555 
community clinics, interventions lacking face-to-face communication between physicians 556 
and pharmacists in the same office, and populations with a greater percentage of 557 
minorities.   558 
 559 
CONCLUSIONS 560 
Instrumental variable methods with combined randomized behavioral studies may 561 
be useful to address unmeasured confounders and to evaluate the effects of different care 562 
processes. Studies with distinct study designs that create more variation in care processes 563 
are needed to address problems of identification. Instrumental variable methods focusing 564 
on individual processes provided larger and stronger outcome relationships than those 565 
found using as-treated methods which are subject to confounding. Further investigation 566 
of the link between care processes such as counseling and drug utilization and outcomes 567 
with rigorous methodology will be helpful to improvement on quality of care.568 
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Table 1 Comparisons of variable values among the intervention group from trial A, the intervention from trial B and the usual care 
groups from both trials 
Variable Intervention group from trial A Intervention group from trial B Usual care groups from both trials 
 N Average (SD) N Average (SD) N Average (SD) 
Outcome 
Systolic blood pressure change (At 6 months – At 
baseline; mm Hg) 
158 -21.24 (19.31) 94 -25.82 (14.07) 243 -10.44 (19.86) 
Diastolic blood pressure change  (At 6 months – 
At baseline; mm Hg) 
158 -9.51 (11.12) 94 -8.94 (8.72) 243 -4.42 (11.46) 
Total treatment costs (2013 US dollar value) 158 792.44 (405.74) 94 772.28 (291.61) 244 510.57 (347.95) 
Process measure 
Number of counseling sessions about lifestyle 
modification by physicians and pharmacists 
158 2.65 (3.38) 94 3.67 (4.24) 244 0.71 (1.98) 
Number of specified-dose antihypertensive 
medications prescribed during the study period 
158 3.93 (2.23) 94 4.49 (2.26) 244 3.09 (1.82) 
Control variables (Baseline characteristic)       
Age (years) 158 58.60 (13.99) 94 59.81 (13.23) 244 61.29 (12.85) 
Number of baseline antihypertensive medications 158 1.19 (1.07) 94 1.45 (0.96) 244 1.73 (0.99) 
Number of co-morbidities
a 
158 0.34 (0.65) 94 0.40 (0.75) 244 0.62 (0.87) 
Systolic blood pressure (mm Hg) 158 154.15 (12.75) 94 152.39 (9.86) 244 150.78 (12.72) 
Diastolic blood pressure (mm Hg) 158 87.18 (11.57) 94 85.00 (11.84) 244 83.10 (11.90) 
 N Percentage
b
 (%)  Percentage
b
 (%)  Percentage
b
 (%) 
Female 158 64.56 94 57.45 244 57.38 
Black 158 5.70 94 0.00 244 10.66 
Other race 158 3.80 94 11.70 244 3.69 
White or Caucasian 158 90.51 94 88.30 244 85.66 
Married or living as married (vs. living alone) 158 67.72 94 59.57 244 54.92 
Current smokers 158 21.52 94 7.45 244 22.54 
Ex-smokers 158 31.01 94 32.98 244 32.79 
Never smoked 158 47.47 94 59.57 244 44.67 
No alcohol intake or less than 1 drink per day (vs. 
≥ 1 drink per day) 
158 90.51 94 78.72 232 86.21 
a 
Co-morbidities included diabetes mellitus, peripheral artery disease, left ventricular hypertrophy, coronary bypass surgery, stroke, chronic kidney                 
  disease, heart failure, angina, and myocardial infarction. 
b 
Percentages do not add up to one for some variables due to rounding. 
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Table 2 Comparisons of process-of-care estimates between IV models, as-treated models, and post-hoc IV models
a
 for each outcome 
Outcome / 
Process measure 
Methods 
As-treated methods IV methods Post-hoc IV methods
a 
Coefficient 
(SE) 
P-
value 
95% CI 
Coefficient 
(SE) 
P-
value 
95% CI 
Coefficient 
(SE) 
P-
value 
95% CI 
SBP change 
No. Counseling 
session 
-0.45 
(0.24) 
0.06 (-0.92, -0.02) 
-10.82 
(14.79) 
0.46 (-39.80, 18.16) 
-5.30
 
(1.13) <0.001 (-7.52, -3.08) 
No. Medications 
-0.05 
(0.46) 
0.92 (-0.94, 0.85) 
10.78 
(23.19) 
0.64 (-34.66, 56.23) 
-7.19
 
(1.57) <0.001 (-10.27, -4.12) 
DBP change 
No. Counseling 
session 
-0.10 
(0.14) 
0.49 (-0.38, 0.18) 
-0.43  
(3.04) 
0.89 (-6.38, 5.53) 
-1.65
 
(0.52) 0.002 (-2.68, -0.63) 
No. Medications 
-0.28 
(0.23) 
0.23 (-0.74, 0.18) 
-1.67  
(5.00) 
0.74 (-11.48, 8.14) 
-2.68
 
(0.81)  0.001 (-4.26, -1.10) 
Total costs 
No. Counseling 
session 
33.02
 
(4.69) 
< 0.001 (23.80, 42.24) 
-383.15 
(677.64) 
0.57 
(-1711.31, 
945.01) 
89.08
 
(14.74) < 0.001 (60.18, 117.98) 
No. Medications 
90.57
 
(8.74) 
< 0.001 (73.41, 107.74) 
832.18 
(1051.69) 
0.43 
(-1229.11, 
2893.46) 
191.81
 
(25.08) < 0.001 (142.66, 240.96) 
a Post-hoc instrumental variable methods included one process measure as an endogenous regressor and the other process measure as a control variable.  
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APPENDIX A: BASELINE CHARACTERISTICS ACROSS TRIALS 
Table A1 Baseline characteristics of subjects across trials 
 
Baseline characteristics 
Trial A (Carter et al. 
2009) 
Trial B (Carter et al. 
2008) 
P-value 
Intervention group (N = 
158) 
Usual care group (N = 
175) 
Intervention group (N = 
94) 
Usual care group (N = 
69) 
 Mean (SD) Mean (SD) 
Age (years) 59.51 (13.77) 61.47 (12.28) 0.12
a 
Number of baseline 
antihypertensive 
medications 
1.53 (1.06) 1.45 (0.98) 0.40
a 
Number of co-
morbidities 
0.52 (0.80) 0.44 (0.78) 0.29
a 
Systolic blood pressure 152.44 (13.44) 151.60 (9.58) 0.48
a 
Diastolic blood pressure 84.78 (12.16) 84.72 (11.39) 0.96
a 
 N (%) N (%)  
Female 202 (60.66) 94 (57.67) 0.52
b 
Black 35 (10.51) 0 (0) < 0.001
b 
Other race 12 (3.60) 14 (8.59) 0.02
b 
White or Caucasian 286 (85.89) 149 (91.41) 0.08
b 
Married or living as 
married 
193 (57.96) 104 (63.80) 0.21
b 
Current smokers 83 (24.92) 13 (7.98) < 0.001
b 
Ex-smokers 108 (32.43) 52 (31.90) 0.91
b 
Never smoked 142 (42.64) 98 (60.12) < 0.001
b 
No alcohol intake or less 
than 1 drink per day 
286 (89.10) 131 (80.37) 0.01
b
 
a
 One-way ANOVA 
b
 Pearson chi-squared test  
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Table A2 Demographic characteristics of excluded patients who did not have complete 6-
month data 
Characteristics 
Trial A (Carter et al. 2009) 
N = 69 
Trial B (Carter et al. 2008) 
N = 16 
 Mean (SD) Mean (SD) 
Age (years) 53.00 (14.44) 52.63 (15.89) 
 N (%) N (%) 
Female 36 (52.17) 7 (43.75) 
Male 33 (47.83) 9 (56.25) 
Black 18 (26.09) 1 (6.25) 
Other race 0 (0) 15 (93.75) 
White or Caucasian 51 (73.91) 0 (0) 
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APPENDIX B: TEST OF HOMOGENEITY 
Table B1 Test of homogeneity using fixed effects (stata command: metan) 
Variable P-value of heterogeneity 
chi-squared test 
Systolic blood pressure change 0.18 
Diastolic blood pressure change 0.15 
Treatment costs 0.06 
Number of counseling sessions about lifestyle modification 0.28 
Number of specified-dose antihypertensive medications 0.05 
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APPENDIX C: ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS 
Table C1 Number of subjects who were adherent and non-adherent to medications 
between the intervention group and the usual care group across trial A and trial B 
Trial Adherent to medications Non-adherent to medications
g 
Intervention 
group 
Usual care 
group 
Intervention 
group 
Usual care 
group 
Trial A
a 98
c 
150
d 
12 14 
Trial B
b 75
e 
54
f 
3 4 
Total 173 204 15 18 
            
a
 No significant difference in adherence between the intervention group and the  
              usual care group in trial A, Pearson chi2(1) = 0.4315, p-value = 0.511 
            
b
 No significant difference in adherence between the intervention group and the  
              usual care group in trial B, Pearson chi2(1) = 0.6340, p-value = 0.426 
            
c
 89% of subjects in the intervention group in trial A were adherent to medications  
              (98 out of 110 subjects) 
            
d
 91% of subjects in the usual care group in trial A were adherent to medications  
              (150 out of 164 subjects) 
            
e
 96% of subjects in the intervention group in trial B were adherent to medications  
              (75 out of 78 subjects) 
            
f
 93% of subjects in the usual care group in trial B were adherent to medications  
              (54 out of 58 subjects) 
           
g
 Non-adherence was determined by answering yes to 3 or more of 5 questions  
              from Morisky adherence scale (Morisky DE, Green LW, Levine DM 1986 and  
              Morisky et al. 1983). 
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Table C2 Number of subjects who were adherent and non-adherent to medications 
between trial A and trial B 
Trial  Adherent to medications
a 
Non-adherent to medications
a 
Trial A 248 (90.51% of trial A) 26 
Trial B 129 (94.85%  of trial B) 7 
a 
No significant difference in adherence between trial A and trial B, Pearson    
              chi2(1) = 2.3152, p-value = 0.128 
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APPENDIX D: FULL PARAMETER ESTIMATES 
Table D1 Parameter estimates from instrumental variable models by outcome 
Outcome SBP change DBP change Total costs 
Model details 
No. observations = 483 
F (14, 468) = 2.38 
P-value = 0.003 
Centered R
2
 = -2.8178 
Uncentered R
2 
= -
1.1494 
No. of observations = 
483 
F (14, 468) = 10.70 
P-value < 0.001 
Centered R
2
 = 0.1835 
Uncentered R
2 
= 0.4154 
No. of observations = 
484 
F (14, 469) = 1.00 
P-value = 0.45 
Centered R
2 
= -17.8580 
Uncentered R
2
 = -
3.8790 
Variable 
Coefficient (SE) 
p-value 
Coefficient (SE) 
p-value 
Coefficient (SE) 
p-value 
Number of 
counseling 
sessions 
-10.82 (14.79) 
0.46 
-0.43 (3.04) 
0.89 
-383.15 (677.64) 
0.57 
Number of 
antihypertensive 
medications 
10.78 (23.19) 
0.64 
-1.67 (5.00) 
0.74 
832.18 (1051.69) 
0.43 
Age 
-0.26 (0.46) 
0.58 
-0.14 (0.10) 
0.15 
-11.33 (19.87) 
0.57 
Female  
-5.54 (6.46) 
0.39 
-1.32 (1.40) 
0.35 
-84.95 (267.53) 
0.75 
Black  
-4.73 (9.84) 
0.63 
-1.22 (2.74) 
0.66 
-245.24 (425.68) 
0.57 
Other race  
18.30 (31.33) 
0.56 
0.08 (6.55) 
0.99 
945.14 (1426.51) 
0.51 
Living alone  
2.80 (4.44) 
0.53 
0.92 (1.06) 
0.39 
92.23 (193.80) 
0.63 
Current smokers  
12.64 (15.15) 
0.40 
-0.45 (3.14) 
0.89 
439.27 (700.52) 
0.53 
Ex-smokers  
1.30 (6.27) 
0.84 
-1.98 (1.56) 
0.21 
190.25 (278.17) 
0.49 
Alcohol: one drink 
or more per day  
2.53 (4.98) 
0.61 
2.52 (1.36) 
0.07 
-15.69 (202.04) 
0.94 
Number of 
baseline 
antihypertensive 
medications 
-10.50 (25.94) 
0.69 
1.98 (5.46) 
0.72 
-745.00 (1186.36) 
0.53 
Number of co-
morbidities 
-2.19 (3.31) 
0.51 
-0.41 (0.84) 
0.62 
-63.20 (141.05) 
0.65 
SBP at baseline 
-1.22 (1.07) 
0.25 
-0.03 (0.23) 
0.91 
-29.87 (47.21) 
0.53 
DBP at baseline 
-0.25 (0.33) 
0.45 
-0.47 (0.08) 
< 0.001 
-8.83 (14.92) 
0.55 
Constant 
201.30 (192.97) 
0.30 
49.90 (39.55) 
0.21 
5334.88 (8520.83) 
0.53 
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Table D2 Parameter estimates from as-treated models by outcome 
Outcome SBP change DBP change Total costs 
Model details 
No. of observations = 
483 
F (14, 468) = 10.58 
P-value < 0.001 
R-squared = 0.2486 
No. of observations = 
483 
F (14, 468) = 9.97 
P-value < 0.001 
R-squared = 0.2529 
No. of observations = 
484 
F (14, 469) = 30.74 
P-value < 0.001 
R-squared = 0.5206 
Variable 
Coefficient (SE) 
p-value 
Coefficient (SE) 
p-value 
Coefficient (SE) 
p-value 
Number of counseling 
sessions 
-0.45 (0.24) 
0.06 
-0.10 (0.14) 
0.49 
33.02 (4.69)
 
<0.001 
Number of 
antihypertensive 
medications 
-0.05 (0.46) 
0.92 
-0.28 (0.23) 
0.23 
90.57 (8.74) 
< 0.001 
Age 
-0.0004 (0.08) 
0.995 
-0.14 (0.05) 
0.01 
0.04 (1.27) 
0.97 
Female  
-3.29 (1.75) 
0.06 
-1.61 (0.99) 
0.10 
63.21 (26.07)
 
0.02 
Black  
-0.48 (4.17) 
0.91 
-1.26 (2.33) 
0.59 
-42.88 (38.62) 
0.27 
Other race  
-2.89 (3.44) 
0.40 
-0.69 (2.06) 
0.74 
112.68 (62.77) 
0.07 
Living alone  
2.13 (1.71) 
0.21 
1.20 (0.96) 
0.21 
17.10 (24.87) 
0.49 
Current smokers  
4.42 (2.25) 
0.051 
-0.08 (1.32) 
0.95 
1.87 (32.51) 
0.95 
Ex-smokers  
-0.89 (1.81) 
0.62 
-1.68 (1.02) 
0.10 
41.78 (29.51) 
0.16 
Alcohol: one drink or 
more per day  
2.13 (2.40) 
0.37 
2.29 (1.35) 
0.09 
-12.31 (32.61) 
0.71 
Number of baseline 
antihypertensive 
medications 
2.26 (1.09) 
0.04 
0.69 (0.56) 
0.22 
62.08 (14.45) 
< 0.001 
Number of co-
morbidities 
-0.82 (1.09) 
0.45 
-0.59 (0.53) 
0.27 
30.33 (17.43) 
0.08 
SBP at baseline 
-0.70 (0.08) 
<0.001 
-0.07 (0.05) 
0.11 
2.22 (1.22) 
0.07 
DBP at baseline 
-0.20 (0.08) 
0.01 
-0.51 (0.05) 
< 0.001 
0.13 (1.34) 
0.92 
Constant 
104.42 (13.44) 
< 0.001 
56.59 (7.98)
 
< 0.001 
-259.52 (208.21) 
0.21 
 
 
 
